北京海润天睿律师事务所 关于中国化学工程股份有限公司 2025 年第二次临时股东会的法律意见书 中国·北京 北京市朝阳区建外大街甲14号广播大厦5/9/10/13/17层 邮政编码：100022 电话：86-10-65219696 传真：86-10-88381869 北京海润天睿律师事务所 关于中国化学工程股份有限公司 2025 年第二次临时股东会的法律意见书 致：中国化学工程股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受中国化学工程股份有限 公司（以下简称"公司"）的委托，指派王彩虹律师、杨苡铭律师出席公司 2025 年第二次临时股东会，并依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》（以下简称"《股东会规则》"）等相关法律、法规、规范性文件及《中国 化学工程股份有限公司章程》（以下简称"《公司章程》")的规定，就公司本 次股东会的召集、召开程序、出席会议人员的资格、召集人资格、表决程序、表 决结果等有关事宜出具本法律意见书。 对本法律意见书，本所及见证律师特作如下声明： 第 1 页 共 6 页 1. 本所 ...

独家深度推荐： 药明康德上市以来股东累套现400亿 实控人方大举套现百亿引市场警惕 北斗院二次"冲A"17家机构突击入股 手握4.59亿现金募资7亿必要性存疑 魏应州家族缔造686亿快消巨头 康师傅两大业务下滑 魏宏丞接棒临挑战 三六零否认财务造假市值两天蒸发65亿 近四年累亏39亿仍分红21亿遭质疑 沐曦股份首日涨近7倍 葛卫东12.5亿重仓押注暴赚211亿 同仁堂卷入磷虾油造假风波陷信任危机 市值450亿不及云南白药一半 纳百川依赖"宁王"毛利率四连降 经营现金流告负货币资金仅1.88亿 东莞银行A股候场17年无果 两年被罚1332万董监高涨薪225万 林清轩三年半砸11亿营销为研发12倍 多次虚假宣传被罚 信邦制药涉单位行贿被起诉 股价两跌停业绩萎靡 陈景河32年全球狂购缔造万亿矿业帝国 紫金矿业有息负债1696亿 天风证券或涉当代集团违规占资被立案 前三季盈利1.53亿 碧桂园前11月交付14万套 境内外债务重组落地有望化债超900亿 广州农商行三年剥离481亿债权减压 半年贷款减值损失31亿 ...

行 业 研 究 / 建 筑 装 饰 / 证 券 研 究 报 告 建筑装饰行业周报 11 月固投累计降幅环比扩大，看好宽松 政策带动需求改善 2025 年 12 月 22 日 【投资要点】 【配置建议】 相关研究 《中央经济会议定调"双宽松"，增量政策 及重点工程有望推进》 2025.12.16 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：王翩翩 证书编号：S1160524060001 证券分析师：郁晾 证书编号：S1160524100004 相对指数表现 -20% -10% 0% 10% 20% 30% 2024/12 2025/6 2025/12 建筑装饰 沪深300 《六部门联合发布促进消费方案，推荐机 器人转型企业》 2025.12.01 《美方就结束俄乌冲突提出 28 点新计划， 继续关注"一带一路"周边地区出海》 2025.11.24 《10 月固投延续下滑，适度宽松的货币政 策持续发力，看好战略工程推进》 2025.11.20 《沉潜与时近，古韵焕新声》 2025.11.16 板块行情回顾：上周建筑装饰（SW）指数下跌 0.1%，全部 A 股指数 上涨 0.03%，板块未 ...

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the sector [1]. Industry Summary - As of October 2025, the production of chemical pharmaceutical raw materials in China reached 313,000 tons, showing a year-on-year decrease of 1.6% [1]. - From January to October 2025, the cumulative production of chemical pharmaceutical raw materials was 3,049,000 tons, reflecting a cumulative growth of 1.3% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1].

Core Viewpoint - China National Chemical Engineering Co., Ltd. (China Chemical) has shown mixed financial performance with a slight increase in revenue and profit, while its financing activities indicate a low level of investor confidence as reflected in the financing balance and stockholder changes [1][2][3]. Financing Summary - On December 19, China Chemical's financing buy-in amounted to 22.93 million yuan, while financing repayment was 35.66 million yuan, resulting in a net financing outflow of 12.73 million yuan [1]. - The total financing and securities balance for China Chemical reached 1.748 billion yuan, which is 3.73% of its market capitalization, indicating a low financing balance compared to the past year [1]. - The company had a high securities lending balance with 120,300 shares remaining, valued at 926,300 yuan, which is above the 60th percentile of the past year [1]. Financial Performance Summary - As of September 30, China Chemical reported a total of 1.35845 billion yuan in revenue for the first nine months of 2025, reflecting a year-on-year growth of 1.26% [2]. - The net profit attributable to shareholders for the same period was 4.232 billion yuan, showing a year-on-year increase of 10.28% [2]. Shareholder and Dividend Information - Since its A-share listing, China Chemical has distributed a total of 9.958 billion yuan in dividends, with 3.305 billion yuan paid out in the last three years [3]. - As of September 30, 2025, the number of shareholders increased to 111,200, up by 19.23%, while the average number of circulating shares per person decreased by 15.74% to 54,562 shares [2][3]. - The second-largest circulating shareholder, Hong Kong Central Clearing Limited, reduced its holdings by 11.2 million shares to 182 million shares [3].

Core Viewpoint - China Chemical's contract signing continues to grow, with a total of 4,332 projects signed and a total contract value of 352.57 billion yuan from January to November 2025, showcasing its strong market presence and technological innovation strategy [2][3][4]. Group 1: Contract Performance - In the first 11 months of 2025, China Chemical signed contracts worth 352.57 billion yuan, with 2,601.92 billion yuan from domestic markets and 923.77 billion yuan from international markets [3][4]. - The construction engineering contracting remains the core business, contributing 340.16 billion yuan from 2,666 contracts, with the chemical engineering sector leading at 286.34 billion yuan from 2,295 contracts [3][4]. - The company has also seen significant contributions from infrastructure and environmental governance, with new contracts worth 476.23 billion yuan and 6.2 billion yuan, respectively [3]. Group 2: Financial Performance - For the first three quarters of 2025, the company achieved revenue of 135.84 billion yuan, a year-on-year increase of 1.26%, and a net profit attributable to shareholders of 4.23 billion yuan, up 10.28% year-on-year, indicating improved operational quality [6]. - The new contract amount of 2,846 billion yuan in the first three quarters has reached 1.53 times the expected revenue for 2024, providing a solid foundation for future performance growth [4]. Group 3: Technological Innovation - China Chemical has invested heavily in R&D, with total R&D expenses reaching 31.22 billion yuan over the past six years, reflecting a commitment to technological innovation [8]. - The company has achieved significant breakthroughs in key technologies, including the development of hexanediamine and high-end environmental catalysts, which have filled domestic technological gaps and reduced reliance on foreign technologies [8][9]. - The successful production of nylon new materials by its subsidiary marks a significant step in reducing dependency on imports and enhancing market competitiveness [9]. Group 4: Strategic Planning - The company aims to "rebuild a higher quality China Chemical in five years," focusing on deepening technological innovation and optimizing its global business layout [10]. - Future strategies include enhancing collaboration among construction engineering, industrial, and modern service sectors, while prioritizing the development of strategic emerging industries such as new energy and new materials [10].

Investment Rating - The report rates the industry as "Overweight" [7] Core Insights - The potential for investment growth in new infrastructure remains significant, with a focus on expanding effective investment space and enhancing private investment vitality [2][3] - Central enterprises are encouraged to identify new growth areas, particularly in renewable energy, aerospace, and low-altitude economy sectors [4] - The government is increasing support for capital in key infrastructure projects, including railways and smart construction initiatives [5] Summary by Relevant Sections Recent Key Reports - The report highlights the importance of strategically expanding investment in new infrastructure and emphasizes the need for a coordinated approach to urbanization and rural revitalization [3][4] Key Company Recommendations - Recommended companies include China Railway, China Communications Construction, and China State Construction, all of which are expected to benefit from high dividend yields and stable growth [8][11] - Specific sectors such as clean rooms, commercial aerospace, and controlled nuclear fusion are highlighted for their growth potential, with recommended stocks including Yaxiang Integration and Shanghai Port [6][10] Macro/Meso/Micro Data - The report indicates a projected increase in broad infrastructure funding by 7.3% in 2025, driven by enhanced fiscal policies and the issuance of special bonds [31][32] - It also notes that the construction industry is experiencing a decline in net profit margins, with a 10% year-on-year decrease in net profit reported [14][15]

Core Viewpoint - The company reported significant contract activity in November, with a total of 10 major contracts exceeding RMB 500 million, indicating strong business performance in the construction and chemical engineering sectors [5][15]. Group 1: Contract Amounts and Types - The total contract amount for the company from January to November reached RMB 352.57 billion, with 4,332 signed projects [9]. - By business type, the sales figures were RMB 8.80 billion for industrial and new materials, and RMB 286.34 billion for construction chemical engineering [11]. - The domestic contract amount was RMB 260.11 billion, while the overseas contract amount was RMB 92.38 billion [11]. Group 2: Major Contracts in November - Major contracts included the Nigeria MIPL fertilizer project EPC contract valued at approximately RMB 15.165 billion, and several contracts related to the Shaanxi Coal Group's clean and efficient coal conversion projects totaling RMB 9.77 billion, RMB 9.23 billion, and RMB 8.97 billion [5][15]. - Other significant contracts included the construction of high-end new materials projects and coal processing projects, with amounts ranging from RMB 5.85 billion to RMB 8.29 billion [16].

Core Viewpoint - China Chemical (601117) has highlighted the superior thermal stability and flame-retardant properties of its subsidiary Hualu New Material's silica-based nano-aerogel products, which are suitable for high safety and energy efficiency requirements in extreme high-temperature environments [1] Group 1: Product Features - The silica-based nano-aerogel products maintain excellent thermal stability and flame-retardant performance under extreme high-temperature conditions [1] - These products are applicable in chemical and metallurgy projects, particularly for high-temperature large-diameter pipeline insulation and other industrial equipment insulation renovation projects [1] Group 2: Product Development - Hualu New Material is continuously developing new products to meet building energy-saving demands [1] - The company has established a complete product line that includes building insulation boards, energy-saving transparent coatings, and multifunctional integrated energy-saving building solutions [1]

12月2日，中国化学工程华陆公司与中国电建集团北京勘测设计研究院有限公司召开交流座谈会，并签署战略合作协议。华陆公司党委副书记、总经理郑 开学与中国电建北京院党委副书记、总经理杨晓辉出席会议，并共同见证签约。双方围绕新型能源与绿色化工的融合发展，以及各自优势领域的协同互补 展开深入交流。华陆公司副总经理姚又省主持会议。 （来源：能源知库） 杨晓辉介绍了中国电建北京院的企业运营情况、发展规划及其在新能源制氢领域的有关业务布局。他表示，华陆公司在化工领域技术积淀深厚、工程经验 丰富，尤其在绿色化工板块具备行业领先的工程集成实力。希望充分发挥中国电建北京院在绿色能源领域的工程经验，与华陆公司在绿色化工领域的突出 能力深度融合，携手拓展市场，共同探索新赛道，推动双方业务迈向更广领域和更高水平。 座谈结束后，中国电建北京院董事会秘书程国瑞、华陆公司专员李永刚代表双方签署战略合作协议。 中国电建北京院董事会办公室、新型储能技术研究中心、新能源工程院、市场经营部，华陆公司经营管理部、材料能源事业部、研发中心等有关部门负责 人参加会议。 郑开学对杨晓辉一行的到访表示欢迎，并高度评价了中国电建北京院在业务发展与工程建设方面取得 ...